FDA GDUFA Testimony Presentation Slides

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-02-2016
Volume 40
Issue 3

Slides from the FDA GDUFA presentation before the Senate Health, Education, Labor and Pensions Committee in January 2016.

Slides from the FDA GDUFA presentation before the Senate Health, Education, Labor and Pensions Committee in January 2016.

External Link - GDUFATestimony_presentationslides.pdf

Articles in this issue
Gaining Insight from Process Control Data
Gaining Insight from Process Control Data
PT0316_Troubleshooting_495forweb.gif
Designing a Biomanufacturing Facility Incorporating Single-Use Technologies
Generic-Drug Production and Oversight Challenge FDA and Manufacturers
Phase-Appropriate GMP
How Important is Data Integrity to Regulatory Bodies?
How Important is Data Integrity to Regulatory Bodies?
FDA GDUFA Testimony Presentation Slides
Keynote Series Addresses Crucial Industry Issues
Polymorph Screening for Identification of Relevant Crystalline Forms
Polymorph Screening for Identification of Relevant Crystalline Forms
Building Consensus for E&L Testing Standards
Building Consensus for E&L Testing Standards
Tecan_225.jpg
Multimode Microplate Reader Improves Sensitivity
Thermo_225.jpg
High-Pressure Ion Chromatography System
Zeiss_225.jpg
Confocal Microscope for Surface Analysis
Pharma Outsourcing Market Expands
Redefining Pharma Agility
Redefining Pharma Agility
Tackling Regulatory Challenges of EU’s Variations Framework
Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Related Content
INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

Patrick Lavery;Feliza Mirasol
April 1st 2025
Article

William Wainwright, business development manager at Iwata Label USA, discusses the practical security benefits of functional labels at INTERPHEX 2025.

Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Culture Biosciences Opens INTERPHEX 2025 with Launch of Cloud-Integrated Mobile Bioreactor

Patrick Lavery
April 1st 2025
Article

The company said the Stratyx 250 is the first bioreactor of its kind to offer biotech companies a combination of automation, remote process control, and flexibility.

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Facing the Latest Patent Cliff

Mike Hennessy Jr.
April 1st 2025
Article

Over the course of the next five years, the bio/pharma industry is expected to see the patents of multiple blockbuster drugs expire, impacting some key industry players.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.